You are here

A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation

Last updated on February 20, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Los Angeles, California, United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Smoking Cessation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects must have smoked on average of at least ten cigarettes per day during the
past year

- Subjects must have no period of abstinence greater than three months in the past year

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects with any history of cardiovascular disease

- Myocardial infarction

- Significant arrhythmias

- Poorly controlled hypertension

NCT00150241
Pfizer
Completed
A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Smoking Cessation
NCT00527150
All Genders
18+
Years
Multiple Sites
Smoking Cessation
NCT00285012
All Genders
35+
Years
Multiple Sites
Smoking Cessation
NCT00143325
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now